Goldman Sachs Group reaffirmed their neutral rating on shares of Henry Schein (NASDAQ:HSIC) in a research report sent to investors on Friday morning.

A number of other analysts have also weighed in on HSIC. Zacks Investment Research upgraded Henry Schein from a hold rating to a buy rating and set a $85.00 target price on the stock in a research note on Tuesday, July 10th. BidaskClub lowered Henry Schein from a buy rating to a hold rating in a research note on Friday, July 13th. Stifel Nicolaus increased their target price on Henry Schein from $76.00 to $81.00 and gave the stock a hold rating in a research note on Tuesday, August 7th. Robert W. Baird increased their target price on Henry Schein from $83.00 to $90.00 and gave the stock an outperform rating in a research note on Tuesday, August 7th. Finally, Craig Hallum increased their target price on Henry Schein from $83.00 to $96.00 and gave the stock a buy rating in a research note on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Henry Schein currently has an average rating of Hold and a consensus target price of $83.83.

HSIC stock traded down $0.78 during midday trading on Friday, reaching $82.51. The company’s stock had a trading volume of 1,337,183 shares, compared to its average volume of 1,662,988. The company has a quick ratio of 0.68, a current ratio of 1.29 and a debt-to-equity ratio of 0.34. Henry Schein has a 1 year low of $62.56 and a 1 year high of $90.52. The firm has a market cap of $12.75 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 2.40 and a beta of 0.97.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Monday, August 6th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. Henry Schein had a return on equity of 20.40% and a net margin of 3.15%. The business had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.31 billion. During the same quarter last year, the firm posted $0.88 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. Research analysts expect that Henry Schein will post 4.12 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. McAdam LLC acquired a new stake in Henry Schein in the third quarter worth about $104,000. NEXT Financial Group Inc acquired a new stake in Henry Schein in the third quarter worth about $103,000. Squar Milner Financial Services LLC acquired a new stake in Henry Schein in the second quarter worth about $120,000. Piedmont Investment Advisors LLC acquired a new stake in Henry Schein in the second quarter worth about $130,000. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Henry Schein by 57.1% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after acquiring an additional 800 shares in the last quarter.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Story: How is an ETF different from a mutual fund?

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.